Chimeric Therapeutics Limited
CHM.AX
Australian Securities Exchange0.06
AUD
+0.00
- -
Chimeric Therapeutics Limited
CHM.AX
(Australian Securities Exchange)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Chimeric Therapeutics Limited (ASX:CHM) is an Australia-based clinical-stage biotechnology company focused on the discovery, development and commercialization of cell therapies for cancer patients. Founded in 2020 and headquartered at Level 3, 62 Lygon Street, Carlton, Victoria, the company advances a diversified portfolio of autologous CAR T-cell therapies and allogeneic natural killer (NK) cell therapies targeting solid tumors and blood cancers; key assets include CHM CDH17, a third-generation CAR T-cell therapy targeting CDH17 in gastrointestinal cancers such as colorectal cancer, gastric cancer and neuroendocrine tumors (in Phase 1/2 trials at US sites including Sarah Cannon Research Institute, University of Pennsylvania and UChicago Medicine); CHM CLTX (chlorotoxin CAR T), utilizing a scorpion venom-derived peptide for solid tumors like glioblastoma; CHM CORE-NK (CHM 0201), an off-the-shelf NK cell platform for acute myeloid leukemia and colorectal cancers (in Phase 1B trials at MD Anderson Cancer Center and Case Western Reserve University); and preclinical candidates like CHM 1301 for ovarian and pancreatic cancers. Operations span Australia and the United States, with intellectual property licensed from institutions including City of Hope, University of Pennsylvania and Case Western Reserve University; the company generates no commercial revenue and relies on equity financings, R&D tax incentives and partnerships. Recent developments include a partnership with Cell Therapies Pty Ltd in 2025 to manufacture CAR T and NK cells at Australia's only commercial-scale facility in Melbourne's Parkville Precinct, enabling local clinical trial access; FDA fast-track designation for CHM CDH17 in gastroenteropancreatic neuroendocrine tumors; US patent allowance for CHM 0201 CORE-NK technology; ethics approval for a multi-site Phase 1/2 CHM CDH17 trial in advanced gastrointestinal cancers; complete response in an AML patient from the CORE-NK Phase 1B ADVENT-AML trial; expansion of ADVENT-AML to newly diagnosed AML patients; $5 million capital raise via share placement in October 2024; appointment of Dr. Rebecca McQualter as CEO in November 2024; and US$2.5 million non-dilutive funding in February 2025 from a philanthropic family office for CHM CDH17.
Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
Imugene secures FDA backing for Azer-cel registration pathway
Kairos Minerals secures mining agreement with Nyamal Aboriginal Corporation for Mt York Gold Project
Chimeric Therapeutics receives $4.5 million R&D tax incentive refund
Altech draws interest from top-tier battery manufacturer as Silumina Anodes™ hit 1,000-cycle mark
Vaultz completes Xapo Bank onboarding